Amyloid & Tau PET Agents¹⁸F-florbetapir / florbetaben / flutemetamol · ¹⁸F-flortaucipir
Imaging the molecular pathology of Alzheimer disease
Quick Answer
Amyloid PET agents (F-18 florbetapir, florbetaben, flutemetamol) bind fibrillar β-amyloid plaques; a negative scan effectively excludes significant amyloid and thus Alzheimer pathology, while a positive scan indicates amyloid but is not specific to symptomatic disease (amyloid prevalence rises with age). Tau PET (F-18 flortaucipir) images neurofibrillary tau, whose burden and topography track symptom stage more closely. Both are read against defined visual criteria (positive = loss of the gray–white distinction from cortical binding) and interpreted with the clinical picture — increasingly to support anti-amyloid therapy selection.
Mechanism
Amyloid ligands bind β-pleated-sheet fibrillar amyloid in cortical plaques; tau ligands bind paired-helical-filament tau in neurofibrillary tangles. In both, cortical gray-matter binding indicates pathology, while nonspecific white-matter uptake is the normal background (all these lipophilic tracers show some white-matter retention). The key read is whether gray-matter cortical signal rises to match or exceed the white matter.
Physics
| Property | Value |
|---|---|
| Isotope / decay | Fluorine-18, β⁺ |
| Half-life | 109.8 min |
| Uptake time | ~30–90 min (agent-specific) |
| Quantification | Centiloid scale (amyloid); SUVr |
Clinical Indications
- Cognitive impairment with diagnostic uncertainty — a negative amyloid scan argues strongly against Alzheimer disease.
- Anti-amyloid therapy patient selection and monitoring (confirm amyloid presence; ARIA surveillance is MRI, not PET).
- Tau PET for staging and topographic correlation with symptoms; research/therapeutic trials.
Preparation & Interpretation Criteria
- Standard PET/CT with agent-specific uptake time; read on approved visual criteria (each amyloid agent has its own).
- Amyloid positive: cortical gray-matter binding that matches or exceeds adjacent white matter (loss of the gray–white junction) in specified regions.
- Tau positive: regional cortical uptake following a Braak-like distribution correlating with severity.
- Centiloid scale standardizes amyloid burden across agents for longitudinal/therapeutic use.
Interpretation Highlights
- The rule-out asymmetry: negative amyloid PET is a powerful rule-out; positive is less specific (age-related prevalence).
- Tau topography tracks clinical stage better than amyloid burden — useful for staging symptomatic disease.
- DAT (ioflupane) SPECT distinguishes DLB (reduced striatal dopamine transporter) from Alzheimer; FDG patterns (temporoparietal vs frontotemporal vs occipital) complement molecular imaging.
Reporting Checklist
- State the agent and its visual criteria; report positive/negative (not degrees) unless quantifying with Centiloid/SUVr.
- For tau, describe regional/Braak-like distribution.
- Explicitly caution that age-related amyloid positivity ≠ symptomatic Alzheimer disease; correlate clinically.
Common Pitfalls
- Equating incidental amyloid positivity with symptomatic Alzheimer disease (prevalence rises with age).
- Misreading nonspecific white-matter uptake as a positive cortical scan.
- Applying one agent's criteria to another — each amyloid tracer has distinct thresholds.
- Off-target tau binding (choroid plexus, basal ganglia, MAO-related) misread as tangles.
Board Pearls
A negative amyloid PET is a powerful rule-out — it effectively excludes significant β-amyloid and therefore Alzheimer pathology. A positive scan is far less specific: amyloid prevalence rises with age, so it must be read with the clinical picture and increasingly with tau PET, whose burden and topography track symptom stage more closely.
Amyloid positivity = cortical gray-matter binding that matches/exceeds white matter (loss of the gray–white junction) in specified regions; nonspecific white-matter uptake is the normal background and must not be over-read. Each amyloid agent has its own approved visual criteria — don't cross-apply.
Tau topography (Braak-like) correlates with clinical stage better than amyloid burden. In the anti-amyloid-therapy era, amyloid PET confirms the target (and the Centiloid scale standardizes burden), but ARIA monitoring is MRI, not PET. DAT SPECT separates DLB (reduced striatal uptake) from Alzheimer; FDG hypometabolic patterns complement the molecular agents. Watch off-target tau binding (choroid plexus, basal ganglia).
Related Pages
- Contrast tracer: FDG (metabolic dementia patterns); related: DAT (ioflupane) SPECT for DLB; disease: Brain FDG / dementia.
Figure / Diagram Suggestions
- A positive vs negative amyloid teaching pair (loss vs preservation of gray–white distinction).
- A Braak-like tau topographic staging map.
- A Centiloid scale reference bar.
Self-Check
Q1. What makes a negative amyloid PET clinically powerful?
Answer: It effectively excludes significant β-amyloid and therefore Alzheimer pathology — a strong rule-out.
Q2. On what visual finding is an amyloid scan called positive?
Answer: Cortical gray-matter binding that matches or exceeds white matter (loss of the gray–white junction) in specified regions.
Q3. Why does tau PET track symptom stage better than amyloid PET?
Answer: Tau burden and topography (Braak-like) correlate with clinical severity, whereas amyloid can be present (age-related) without symptoms.
Q4. Which nuclear study distinguishes dementia with Lewy bodies from Alzheimer disease?
Answer: DAT (ioflupane) SPECT — reduced striatal dopamine-transporter uptake in DLB, preserved in Alzheimer.
Evidence & sources
https://nuc.med/amyloid-tau-pet/ Report an issue